BPA Biosante Pharmaceuticals

The Wall Street Transcript has published an in-depth interview with Stephen M. Simes, president and CEO of BioSante Pharmaceuticals, Inc. (AMEX:BPA) in which he talks at length about the Company. The entire 2,500 word interview is available free online at http://www.twst.com/ceos.htm. BioSante is developing a pipeline of hormone therapy products to treat both men and women. BioSante�s hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including avian flu and biodefense vaccines for toxins such as anthrax, and drug delivery systems. Regarding the company�s objectives Mr. Simes stated, �Our focus today is in hormone therapy products. We recently received FDA approval of our first product, Elestrin�, which is an estrogen gel approved for the treatment of hot flashes in menopausal women, a $1.3 billion market. Elestrin will be the lowest dose of estradiol on the market to treat hot flashes. Elestrin will be launched in mid-2007. In addition, we have initiated a Phase III clinical trial of LibiGel�, our testosterone gel, for the treatment of female sexual dysfunction, a potential $2.0 billion market. We also are working on our calcium phosphate-based nanotechnology in the area of improved vaccines and protein delivery.� When asked about the company�s current position Mr. Simes stated, �The business plan right now is to introduce our transdermal estradiol gel, Elestrin, through Bradley Pharmaceuticals, (NYSE:BDY) and conduct our Phase III clinical trials of LibiGel for the treatment of female sexual dysfunction. One of the key parts of operating a small company like ours is focus, and this is our focus.� The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this news release that are not historical in nature, particularly those that utilize terminology such as "may," "will," "should," "likely," "expects," "anticipates," "estimates," "believes," "plans," "hopes," or comparable terminology, are forward-looking statements. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that cause actual results to differ materially from those expressed in such forward-looking statements are the difficulty of developing pharmaceutical products, the success of clinical testing, obtaining regulatory and other approvals and achieving market acceptance, and other factors identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed in BioSante's most recent Forms 10-K and 10-Q, which discussion also is incorporated herein by reference. All forward-looking statements speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.